Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizoaffective disorder: Findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study (American Journal of Psychiatry (September 15, 2008) (1420-1431) doi:10.1176/appi.ajp.2008.08050756);Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizoaffective disorder: Findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study

American Journal of Psychiatry

Volumn 165, Issue 11, 2008, Pages 1420-1431

  Sikich, Linmarie ^a   Frazier, Jean A ^b   McClellan, Jon ^b   Findling, Robert L ^b   Vitiello, Benedetto ^b   Ritz, Louise ^b   Ambler, Denisse ^b   Puglia, Madeline ^b   Maloney, Ann E ^b   Michael, Emily ^b   De Jong, Sandra ^b   Slifka, Karen ^a   Noyes, Nancy ^a   Hlastala, Stefanie ^b   Pierson, Leslie ^b   McNamara, Nora K ^b   Delporto Bedoya, Denise ^b   Anderson, Robert ^b   Hamer, Robert M ^b   Lieberman, Jeffrey A ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE; MOLINDONE; OLANZAPINE; RISPERIDONE;

ADOLESCENT; ADULT; AKATHISIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTICHOLINERGIC INDUCED URINARY RETENTION; ANXIETY DISORDER; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EARLY ONSET SCHIZOPHRENIA; FEMALE; HUMAN; INSULIN BLOOD LEVEL; IRRITABILITY; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROLOGIC DISEASE; ONSET AGE; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SUICIDAL BEHAVIOR; URINE RETENTION; WEIGHT GAIN;

EID: 55749083565     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2008.08050756     Document Type: Erratum

References (49)

1. American Academy of Child and Adolescent Psychiatry: Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 2001; 40(Suppl 7):4S-23S
2. Frazier JA, McClellan J, Findling RL, Vitiello B, Anderson R, Zablotsky B, Williams E, McNamara NK, Jackson JA, Ritz L, Hlastala SA, Pierson L, Varley JA, Puglia M, Maloney AE, Ambler D, Hunt-Harrison T, Hamer RM, Noyes N, Lieberman JA, Sikich L: Treatment of Early-Onset Schizophrenia Spectrum disorders (TEOSS): demographic and clinical characteristics. J Am Acad Child Adolesc Psychiatry 2007; 46:979-988
3. Röpcke B, Eggers C: Early-onset schizophrenia: a 15-year follow-up. Eur Child Adolesc Psychiatry 2005; 14:341-350
4. Remschmidt H, Martin M, Fleischhaker C, Theisen FM, Hennighausen K, Gutenbrunner C, Schulz E: Forty-two-years later: the outcome of childhood-onset schizophrenia. J Neural Transm 2007; 114:505-512
5. Fleischhaker C, Schulz E, Tepper K, Martin M, Hennighausen K, Remschmidt H: Long-term course of adolescent schizophrenia. Schizophr Bull 2005; 31:769-780
6. McClellan J, McCurry C, Snell J, DuBose A: Early-onset psychotic disorders: course and outcome over a 2-year period. J Am Acad Child Adolesc Psychiatry 1999; 38:1380-1388
7. Kyriakopoulos M, Frangou S: Pathophysiology of early onset schizophrenia. Int Rev Psychiatry 2007; 19:315-324
8. Olfson M, Blanco C, Liu L, Moreno C, Laje G: National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 2006; 63:679-685
9. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators: effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353:1209-1223
10. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW: Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63:1079-1087
11. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Grobbee DE; EUFEST study group: Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008; 371:1085-1097
12. Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey PD, Kopala L, McGorry PD, Van Hove I, Eerdekens M, Swyzen W, De Smedt G; Early Psychosis Global Working Group: Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry 2005; 162:947-953
13. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R, Wei H, Hamer RM; HGDH Study Group: Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003; 160:1396-1404
14. Emsley RA: Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study: Risperidone Working Group. Schizophr Bull 1999; 25:721-729
15. Sanger TM, Lieberman JA, Tohen M, Grundy S, Beasley C Jr, Tollefson GD: Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry 1999; 156:79-87
16. Crespo-Facorro B, Pérez-Iglesias R, Ramirez-Bonilla M, Martínez-García O, Llorca J, Luis Vázquez-Barquero J: A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis. J Clin Psychiatry 2006; 67:1511-1521
17. Pool D, Bloom W, Mielke DH, Roniger JJ Jr, Gallant DM: A controlled evaluation of loxitane in seventy-five adolescent schizophrenic patients. Curr Ther Res Clin Exp 1976; 19:99-104
18. Spencer EK, Campbell M: Children with schizophrenia: diagnosis, phenomenology, and pharmacotherapy. Schizophr Bull 1994; 20:713-725
19. Keepers GA, Clappison VJ, Casey DE: Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch Gen Psychiatry 1983; 40:1113-1117
20. Meltzer HY, Rabinowitz J, Lee MA, Cola PA, Ranjan R, Findling RL, Thompson PA: Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance. Am J Psychiatry 1997; 154:475-482
21. Kryzhanovskaya L, Schulz C, McDougle CJ, Frazier J, Shen J, Dittman R, Robertson-Plouch C, Bauer T, Xu W, Wang WV, Carlson J, Corya S, Tohen M: A double-blind, placebo-controlled study of olanzapine in adolescents with schizophrenia. Neuropsychopharmacology 2005; 30(Suppl 1):S258-S259
22. Haas M, Unis AS, Copenhaver M, Quiroz J, Kushner S, Kusumakar V: Efficacy and safety of risperidone in adolescents with schizophrenia, in 2007 Annual Meeting New Research Program and Abstracts. Arlington, Va, American Psychiatric Association, 2007, pp 221-222
23. Robb AS, Findling RL, Nyilas M, Forbes RA, McQuade RD, Mallikaarjun S, Pikalov A, Marcus R, Carson W: Efficacy of aripiprazole in the treatment of adolescents with schizophrenia, in 2007 Annual Meeting New Research Program and Abstracts. Arlington, Va, American Psychiatric Association, 2007, pp 319-320
24. Findling RL, Robb AS, Nyilas M, Forbes RA, McQuade RD, Mallikaarjun S, Pikalov A, Marcus R, Carson W: Tolerability of aripiprazole in the treatment of adolescents with schizophrenia, in 2007 Annual Meeting New Research Program and Abstracts. Arlington, Va, American Psychiatric Association, 2007, p 319
25. Kumra S, Frazier JA, Jacobsen LK, McKenna K, Gordon CT, Lenane MC, Hamburger SD, Smith AK, Albus KE, Alaghband-Rad J, Rapoport JL: Childhood-onset schizophrenia: a doubleblind clozapine-haloperidol comparison. Arch Gen Psychiatry 1996; 53:1090-1097
26. Shaw P, Sporn A, Gogtay N, Overman G, Greenstein D, Gochman P, Tossell J, Lenane M, Rapoport JL: Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry 2006; 63:721-730
27. Sporn A, Gogtay N, Ortiz-Aguayo R, Alfaro C, Tossell J, Lenane M, Gochman P, Rapoport JL: Clozapine-induced neutropenia in children: management with lithium carbonate. J Child Adolesc Psychopharmacol 2003; 13:401-404
28. McClellan J, Sikich L, Findling RL, Frazier JA, Vitiello B, Hlastala SA, Williams E, Ambler D, Hunt-Harrison T, Maloney AE, Ritz L, Anderson R, Hamer RM, Lieberman JA: Treatment of Early-Onset Schizophrenia Spectrum disorders (TEOSS): rationale, design, and methods. J Am Acad Child Adolesc Psychiatry 2007; 46:969-978
29. Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261-276
30. Matzner F, Silva R, Silvan M, Chowdhury M, Nastasi L: Preliminary test-retest reliability of the KID-SCID, in 1997 Annual Meeting New Research Program and Abstracts. Washington, DC, American Psychiatric Association, 1997, pp 172-173
31. First MB, Spitzer RL, Gibbon M, Williams JB: User's Guide for the Structured Clinical Interview for DSM-IV Axis I Disorders Research Version (SCID-I). New York, New York State Psychiatric Institute, Biometrics Research, 1996
32. Werry JS, McClellan JM, Chard L: Childhood and adolescent schizophrenic, bipolar, and schizoaffective disorders: a clinical and outcome study. J Am Acad Child Adolesc Psychiatry 1991; 30:457-465
33. Rating scales and assessment instruments for use in pediatric psychopharmacology research. Psychopharmacol Bull 1985; 21:714-1124
34. Hughes CW, Rintelmann J, Emslie GJ, Lopez M, MacCabe N: A revised anchored version of the BPRS-C for childhood psychiatric disorders. J Child Adolesc Psychopharmacol 2001; 11:77-93
35. Hodges K: Child and Adolescent Functional Assessment Scale. Ypsilanti, Mich, Eastern Michigan University, Department of Psychology, 1990
36. Kalachnik JE: Medication monitoring procedures: thou shall, here's how, in Pharmacotherapy and Mental Retardation. Edited by Gadow KD and Poling AD. Boston, College-Hill, 1988, pp 231-268
37. Simpson GM, Angus JW: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212:11-19
38. Barnes TR: A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154:672-676
39. Williams CL, Hayman LL, Daniels SR, Robinson TN, Steinberger J, Paridon S, Bazzarre T: Cardiovascular health in childhood: a statement for health professionals from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2002; 106:143-160
40. Emsley R, Oosthuizen PP, Kidd M, Koen L, Niehaus DJ, Turner HJ: Remission in first-episode psychosis: predictor variables and symptom improvement patterns. J Clin Psychiatry 2006; 67:1707-1712
41. Lieberman J, Jody D, Geisler S, Alvir J, Loebel A, Szymanski S, Woerner M, Borenstein M: Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry 1993; 50:369-376
42. Kumra S, Kranzler H, Gerbino-Rosen G, Kester HM, De Thomas C, Kafantaris V, Correll CU, Kane JM: Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol Psychiatry 2008; 63:524-529
43. Kryzhanovskaya L, Schulz C, McDougle CJ, Frazier JA, Dittmann RW, Robertson-Pouch C, Bauer T, Xu W, Wang WV, Carlson J, Risser R, Tohen M: Efficacy and safety of olanzapine in adolescents with schizophrenia: results from a 6-week double-blind, placebo-controlled trial, in 2006 Annual Meeting New Research Program and Abstracts. Arlington, Va, American Psychiatric Association, 2006, p 161
44. Ross RG, Novins D, Farley GK, Adler LE: A 1-year open-label trial of olanzapine in school-age children with schizophrenia. J Child Adolesc Psychopharmacol 2003; 13:301-309
45. Emsley R, Rabinowitz J, Medori R: Time course for antipsychotic treatment response in first-episode schizophrenia. Am J Psychiatry 2006; 163:743-745
46. Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Sniadecki JL, Kane JM: Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr Res 2008; 102:230-240
47. Correll CU, Malhotra AK, Kaushik S, McMeniman M, Kane JM: Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry 2003; 160:2063-2065
48. Chang YC, Lane HY, Yang KH, Huang CL: Optimizing early prediction for antipsychotic response in schizophrenia. J Clin Psychopharmacol 2006; 26:554-559
49. Leucht S, Busch R, Kissling W, Kane JM: Early prediction of antipsychotic nonresponse among patients with schizophrenia. J Clin Psychiatry 2007; 68:352-360